deferoxamine has been researched along with homovanillic acid in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ben-Shachar, D; Eshel, G; Finberg, JP; Youdim, MB | 1 |
| Delogu, MR; Desole, MS; Esposito, G; Miele, E; Miele, M; Migheli, R; Rocchitta, G; Serra, PA | 1 |
| Ben Shachar, D; Stephenson, G; Youdim, MB | 1 |
3 other study(ies) available for deferoxamine and homovanillic acid
| Article | Year |
|---|---|
The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Deferoxamine; Dopamine; Homovanillic Acid; Hydroxydopamines; Iron Chelating Agents; Male; Nerve Degeneration; Neurons; Neurotoxins; Oxidopamine; Rats; Rats, Inbred Strains; Substantia Nigra | 1991 |
A study on the role of nitric oxide and iron in 3-morpholino-sydnonimine-induced increases in dopamine release in the striatum of freely moving rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; Animals; Ascorbic Acid; Corpus Striatum; Deferoxamine; Dialysis Solutions; Dopamine; Dose-Response Relationship, Drug; Free Radical Scavengers; Homovanillic Acid; Iron; Male; Metalloporphyrins; Molsidomine; Movement; Nitric Oxide; Nitric Oxide Donors; Rats; Rats, Wistar; Uric Acid | 2001 |
Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Behavior, Animal; Brain; Brocresine; Chromatography, High Pressure Liquid; Deferoxamine; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Exploratory Behavior; Functional Laterality; Homovanillic Acid; Iron; Iron Chelating Agents; Levodopa; Male; Motor Activity; Neurodegenerative Diseases; Neurotransmitter Agents; Oxidopamine; Parkinson Disease; Piperazines; Quinolines; Rats; Rats, Sprague-Dawley; Time Factors | 2004 |